You are here: Industry Insights > BNT162B2

News List

WHO issues alert for falsified COVID-19 vaccine europeanpharmaceuticalreview
March 30, 2021
The World Health Organization (WHO) has warned that a falsified COVID-19 vaccine, identified as Pfizer’s BNT162b2, could still be in circulation in the Americas.
Pfizer and BioNTech begin Covid-19 vaccine trial in pregnant women pharmaceutical-technology
February 20, 2021
Pfizer and BioNTech have dosed the first participants in a global Phase II / III study of their vaccine in preventing Covid-19 in healthy pregnant women aged 18 and above.
Pfizer-BioNTech’s Covid-19 vaccine-immunised sera neutralises SA variant pharmaceutical-technology
February 18, 2021
Pfizer and BioNTech have reported results from an in vitro study, which showed the capability of sera from individuals immunised with their Covid-19 vaccine (BNT162b2) in neutralising SARS-CoV-2 with the South African variant spike protein.
Pfizer, BioNTech Study Shows COVID-19 Vaccine Elicits Antibodies that Neutralize New U.K. Strain americanpharmaceuticalreview
January 22, 2021
Pfizer and BioNTech announced results from an in vitro study that provides additional data on the capability of sera from individuals immunized with the Pfizer-BioNTech COVID-19 vaccine BNT162b2 to neutralize the SARS-CoV-2 U.K. strain, also known ...
Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application worldpharmanews
December 17, 2020
EMA's human medicines committee (CHMP) and its experts have been working intensively over the past weeks to evaluate data submitted by BioNTech and Pfizer in the context of the conditional marketing authorisation (CMA) application for BNT162b2 ...
Safety and efficacy data from Phase III trial of BNT162b2 vaccine published europeanpharmaceuticalreview
December 15, 2020
Pfizer and BioNTech’s data on BNT162b2, their COVID-19 vaccine, has been published in a new scientific paper, demonstrating its 95 percent efficacy rate.
FDA grants Emergency Use Authorization for Pfizer’s COVID-19 vaccine BNT162b2 europeanpharmaceuticalreview
December 15, 2020
The US has approved emergency use of Pfizer and BioNTech’s COVID-19 vaccine, BNT162b2, in people 16 years of age and older.
Health Canada authorises Pfizer and BioNTech’s Covid-19 vaccine pharmaceutical-technology
December 10, 2020
Health Canada has authorised Pfizer and its German partner BioNTech’s Covid-19 vaccine, BNT162b2, reaching a critical milestone in its fight against the pandemic.
Pfizer-BioNTech can use UK as test bed for cold chain distribution: GlobalData expresspharma
December 03, 2020
The country’s small size, dense population and strong healthcare infrastructure should mean distribution of the vaccine with cold chain should go smoothly.
EMA receives application for conditional marketing authorisation of COVID-19 mRNA vaccine BNT162b2 worldpharmanews
December 02, 2020
EMA has received an application for conditional marketing authorisation (CMA) for BNT162b2, a COVID‑19 mRNA vaccine developed by BioNTech and Pfizer.

Previous page 1 2 3 Next page